Clinical Research For Biopharma Clients

In choosing a clinical research and development partner, different clients have different needs. Unchanging, however, is the requirement for transparency, communication, and dependable, high-quality results. Having grown from a core capability of clinical conduct excellence, CNS’ Advanced Phase Research centers (Phase 2-4) and Comprehensive Phase One (CPO) have confidently advanced to provide strategic planning and specialized CRO services, including medical writing, biostatistics, and data management, led by seasoned project managers with experience as sponsors themselves.

From this foundation of commitment, long-term relationships can best evolve to serve the shared interests of both the sponsor and CNS. This shared interest is particularly evident in the development and conduct of trials to first characterize a potential therapy (Phase 1), and in the study of illnesses using subjective assessments where a potentially significant placebo effect is a common concern (Phase 2 and 3, Psychiatric indications). From a platform of Collaborative Centralization in budgeting, contracting, quality assurance, training, and recruiting, CNS provides all sponsors access to deep clinical research experience, from which scientific and practical feedback on strategy and protocol designs are routinely requested. Added to these operational efficiencies is the allegiance to, and care for, those individuals with central nervous system disorders who are particularly special given their choice to participate in clinical research.

For large biopharmaceutical clients, CNS has built on its strong reputation in clinical execution to a clearly innovative development company, able to move ‘shelf’ compounds from first-in-human through Proof of Concept within a single organization. For smaller clients, CNS serves as an important partner supporting medical and development strategy decisions with industry-experienced professional and clinical conduct, including early human testing, indication selection, and concept proof. In further focused commitment, CNS stands as an organization with an unmatched record of conducting successful Phase 1 studies in schizophrenia. CNS’ offerings in Clinical Development continue to seek alignment with professional and governmental organizations, such as the FDA and its Critical Path Initiative, in creating novel scientific and business models which advance the biopharmaceutical sciences.